(8alpha,9beta,11beta,14beta,20R,23S,24R)-11,23,24,25-Tetrahydroxydammar-13(17)-en-3-one(CAS: 19885-10-0)

This compound (CAS 19885-10-0) falls under the scope of REACH regulations in the EU, requiring registration if used in quantities above certain thresholds. For workplace safety, it must comply with the GHS classification, which includes specific handling and labeling requirements. In the US, the FDA and EPA may regulate its use in pharmaceuticals and environmental releases, respectively.

There are alternative reagents and synthetic routes that can be used to prepare similar compounds. For instance, dammarane derivatives with different functional groups can be synthesized using various isomers and analogs. Common alternatives include using 20(R)-dammar-20,25-diene-3-one as a precursor, which can be manipulated through various transformations.

The market for this compound shows growing interest in its potential pharmaceutical applications. Research trends are focused on its use as a bioactive molecule with anti-inflammatory and anti-tumor properties. However, due to its complex structure, the cost and availability remain significant challenges. Emerging research focuses on developing more efficient synthesis methods and understanding its biological mechanisms.

Waste containing this compound should be collected in appropriate containers and managed according to local environmental regulations. Incineration is a common disposal method, but it must be conducted in a controlled manner to prevent the release of harmful substances. Alternatively, professional waste disposal services can be used, ensuring compliance with both regulatory and environmental protection standards. Adequate precautions should be taken to protect the environment and human health during handling and disposal.